Evidence map›Paper›PMID 32731426›Full record

ArticleCancers2020

The Perceived Impact of Length of the Diagnostic Pathway Is Associated with Health-Related Quality of Life of Sarcoma Survivors: Results from the Dutch Nationwide SURVSARC Study.

Vicky L M N Soomers, Ingrid M E Desar, Lonneke V van de Poll-Franse, Michiel A J van de Sande, Jacco J de Haan, Cornelis Verhoef, Ingeborg J H Vriens, Winan J van Houdt, Johannes J Bonenkamp, Winette T A van der Graaf and 1 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vicky L M N SoomersDepartment of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-0019-3968
Ingrid M E DesarDepartment of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Lonneke V van de Poll-FranseDepartment of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-0413-6872
Michiel A J van de SandeDepartment of Orthopedics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-9156-7656
Jacco J de HaanDepartment of Medical Oncology, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands.
Cornelis VerhoefDepartment of Surgical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Ingeborg J H VriensDepartment of Medical Oncology, Maastricht University Medical Centre, 6229 HX Maastricht, The Netherlands.
Winan J van HoudtDepartment of Surgical Oncology, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The Netherlands.ORCID 0000-0002-2303-3468
Johannes J BonenkampDepartment of Surgical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Winette T A van der GraafDepartment of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Olga HussonDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-1387-8686

Funding

KWF Kankerbestrijding kun2015-7527Nederlandse Organisatie voor Wetenschappelijk Onderzoek 198.007Nederlandse Organisatie voor Wetenschappelijk Onderzoek 480-08-009radboud institute of health sciences junior research grantZonMw 2016/04981/zonmw-91101002
6 · The paper itself

Abstract

backgroundSarcoma patients often experience a long time to diagnosis, known as the total interval. This interval can be divided into the patient (time from symptoms to doctor consultation) and diagnostic intervals (time from first consultation to diagnosis). In other cancers, a long total interval has been associated with worse outcomes, but its effect on health-related quality of life (HRQoL) has never been investigated among sarcoma patients. This study investigates the association between (1) the actual time to diagnosis and HRQoL; (2) the perceived impact of the diagnostic interval length and HRQoL; (3) the actual length and perceived impact of the length and the HRQoL of sarcoma survivors.

methodsA cross-sectional study was performed among sarcoma patients aged ≥18, diagnosed 2-10 years ago in the Netherlands. The participants completed a questionnaire on HRQoL, the time to diagnosis, the perceived impact of the diagnostic interval on HRQoL, and coping.

results1099 participants were included (response rate, 58%). The mean time since diagnosis was 67.4 months. More than half reported a patient (60%) or diagnostic interval (55%) ≥1 month. A third (31%) perceived a negative impact of the diagnostic interval length on HRQoL. Patient or diagnostic interval length was not associated with HRQoL. By contrast, participants perceiving a negative impact (32%) had lower HRQoL scores than those perceiving a positive (11%) or no impact (58%) (

conclusionThe perceived impact of the diagnostic interval length was associated with the HRQoL of sarcoma survivors, whereas the actual length was not associated with HRQoL. Maladaptive coping strategies were independently associated with HRQoL. This offers opportunities for early intervention to improve HRQoL.

Indexed as

diagnostic intervalhealth-related quality of lifesarcomatime to diagnosis

Identifiers

PMID32731426
PMCPMC7465613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.